Prelude Therapeutics Inc reports results for the quarter ended in September - Earnings Summary

Prelude Therapeutics Incorporated

12/11/2021 14:32

* Prelude Therapeutics Inc  PRLD.OQ  reported a quarterly
adjusted loss of 66 cents​​ per share for the quarter ended in
September. The mean expectation of four analysts for the quarter
was for a loss of 62 cents per share.
* Reported revenue was zero​;  analysts expected zero. 
* Prelude Therapeutics Inc's reported EPS for the quarter was a
loss of 66 cents​.
* The mean earnings estimate of analysts had fallen by
about 1.1% in the last three months.​ 
* In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
* Prelude Therapeutics Inc shares had fallen by 46.4% this
quarter and lost 76.6% so far this year.
* The company reported a quarterly loss of $30.69 million.
* Wall Street's median 12-month price target for Prelude
Therapeutics Inc is $47.50 
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 4 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
This summary was machine generated November 12 at 02:31 p.m.
 ​All figures in US dollars unless otherwise stated